Takeda
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).
Takeda: 408 sponsored US clinical trials, 49 recruiting.
Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.
Top-decile sponsor footprint
Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
408 total, page 5 of 9
Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
NCT02669121
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
NCT02769065
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
NCT02620046
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants
NCT02706834
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
NCT02661490
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
NCT02611817
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
NCT02611830
OTIS Vedolizumab Pregnancy Exposure Registry
NCT02678052
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
NCT02614586
Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study
NCT02584569
Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
NCT02381288
TAK-935 Multiple Rising Dose Study in Healthy Participants
NCT02539134
Phase 1, Febuxostat XR Relative Bioavailability Study
NCT02504320
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
NCT02467270
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
NCT02477020
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
NCT02497235
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
NCT02497469
A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
NCT02480439
Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
NCT02461160
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
NCT02312258
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
NCT02430870
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
NCT02425111
Entyvio (Vedolizumab) Long Term Safety Study
NCT02674308
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
NCT02413255
Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants
NCT02396147
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
NCT02382640
Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
NCT02475278
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
NCT02284906
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
NCT02371980
Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants
NCT02389881
Food Effect Study of Febuxostat XR in Healthy Participants
NCT02374164
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
NCT02193087
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
NCT02181413
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
NCT02170220
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
NCT02201056
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
NCT02162758
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
NCT02209506
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
NCT02176486
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants
NCT02153099
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
NCT02163915
Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults
NCT02142504
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
NCT02128490
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
NCT02139046
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
NCT02096458
Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
NCT02064907
Fasiglifam 25 mg BID vs 50 mg QD
NCT01982253
MLN3126 Single Rising Dose Study
NCT02447458
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
NCT01931566
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
NCT01892189
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
NCT01900522
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 90 |
| Phase 3 | 148 |
| Phase 4 | 26 |
What is open in the Takeda pipeline
49 recruiting of 408 indexed (12% open); 284 completed (70%).
Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).
Top condition: Healthy Volunteers (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Takeda: open-pipeline peers nationwide
Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 408 trials (± recruiting share)
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Arcus Biosciences · 12% recruiting · 25 trials
- Ardelyx · 12% recruiting · 25 trials
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- East Carolina University · 12% recruiting · 58 trials
Related
What to do with this Takeda page
408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.
- 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.